{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:55:36Z","timestamp":1792788936923,"version":"4.5.0"},"reference-count":171,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T00:00:00Z","timestamp":1504137600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s40264-017-0590-6","type":"journal-article","created":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T12:09:41Z","timestamp":1504181381000},"page":"19-75","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":152,"title":["Dopamine Agonists and Impulse Control Disorders: A Complex Association"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0722-7243","authenticated-orcid":false,"given":"Marie","family":"Grall-Bronnec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Victorri-Vigneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Donnio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Leboucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Rousselet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Thiabaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Zreika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Derkinderen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Challet-Bouju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,31]]},"reference":[{"key":"590_CR1","volume-title":"Rang & Dale\u2019s pharmacology","author":"HP Rang","year":"2012","unstructured":"Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G. Rang & Dale\u2019s pharmacology. 7th ed. Edinburgh: Elsevier Churchill Livingstone; 2012.","edition":"7"},{"issue":"1","key":"590_CR2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.physbeh.2011.04.055","volume":"104","author":"JE Ahlskog","year":"2011","unstructured":"Ahlskog JE. Pathological behaviors provoked by dopamine agonist therapy of Parkinson\u2019s disease. Physiol Behav. 2011;104(1):168\u201372.","journal-title":"Physiol Behav"},{"issue":"4","key":"590_CR3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/syn.21805","volume":"69","author":"P Seeman","year":"2015","unstructured":"Seeman P. Parkinson\u2019s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse. 2015;69(4):183\u20139.","journal-title":"Synapse"},{"issue":"3","key":"590_CR4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10899-009-9123-2","volume":"25","author":"AJ Holman","year":"2009","unstructured":"Holman AJ. Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia. J Gambl Stud. 2009;25(3):425\u201331.","journal-title":"J Gambl Stud"},{"issue":"6","key":"590_CR5","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ejpn.2016.08.006","volume":"20","author":"F Porta","year":"2016","unstructured":"Porta F, Ponzone A, Spada M. Long-term safety and effectiveness of pramipexole in tetrahydrobiopterin deficiency. Eur J Paediatr Neurol. 2016;20(6):839\u201342.","journal-title":"Eur J Paediatr Neurol."},{"issue":"4","key":"590_CR6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/1520-6394(2000)11:4<185::AID-DA8>3.0.CO;2-H","volume":"11","author":"S Seedat","year":"2000","unstructured":"Seedat S, Kesler S, Niehaus DJ, Stein DJ. Pathological gambling behaviour: emergence secondary to treatment of Parkinson\u2019s disease with dopaminergic agents. Depress Anxiety. 2000;11(4):185\u20136.","journal-title":"Depress Anxiety."},{"key":"590_CR7","doi-asserted-by":"crossref","unstructured":"Molina JA, Sainz-Artiga MJ, Fraile A, Jimenez-Jimenez FJ, Villanueva C, Orti-Pareja M, et al. Pathologic gambling in Parkinson\u2019s disease: a behavioral manifestation of pharmacologic treatment?. Mov Disord. 2000;15(5):869\u201372.","DOI":"10.1002\/1531-8257(200009)15:5<869::AID-MDS1016>3.0.CO;2-I"},{"issue":"12","key":"590_CR8","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/mds.21611","volume":"22","author":"DA Gallagher","year":"2007","unstructured":"Gallagher DA, O\u2019Sullivan SS, Evans AH, Lees AJ, Schrag A. Pathological gambling in Parkinson\u2019s disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord. 2007;22(12):1757\u201363.","journal-title":"Mov Disord"},{"issue":"1","key":"590_CR9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/JCP.0000000000000444","volume":"36","author":"M Grall-Bronnec","year":"2016","unstructured":"Grall-Bronnec M, Sauvaget A, Perrouin F, Leboucher J, Etcheverrigaray F, Challet-Bouju G, et al. Pathological gambling associated with aripiprazole or dopamine replacement therapy: do patients share the same features? A review. J Clin Psychopharmacol. 2016;36(1):63\u201370.","journal-title":"J Clin Psychopharmacol."},{"issue":"7","key":"590_CR10","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1212\/01.wnl.0000238503.20816.13","volume":"67","author":"V Voon","year":"2006","unstructured":"Voon V, Hassan K, Zurowski M, de Souza M, Thomsen T, Fox S, et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson\u2019s disease. Neurology. 2006;67(7):1254\u20137.","journal-title":"Neurology."},{"issue":"4","key":"590_CR11","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s11910-006-0022-y","volume":"6","author":"D Weintraub","year":"2006","unstructured":"Weintraub D, Potenza MN. Impulse control disorders in Parkinson\u2019s disease. Curr Neurol Neurosci Rep. 2006;6(4):302\u20136.","journal-title":"Curr Neurol Neurosci Rep."},{"key":"590_CR12","unstructured":"APA. Diagnostic and statistical manual of mental disorders, fifth edition. Washington, DC: APA; 2013."},{"issue":"1","key":"590_CR13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2174\/1574884708666131111202954","volume":"9","author":"M Atmaca","year":"2014","unstructured":"Atmaca M. Drug-induced impulse control disorders: a review. Curr Clin Pharmacol. 2014;9(1):70\u20134.","journal-title":"Curr Clin Pharmacol."},{"issue":"2","key":"590_CR14","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/WNF.0b013e31820d6699","volume":"34","author":"D Dang","year":"2011","unstructured":"Dang D, Cunnington D, Swieca J. The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome. Clin Neuropharmacol. 2011;34(2):66\u201370.","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"590_CR15","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10072-011-0605-5","volume":"32","author":"G d\u2019Orsi","year":"2011","unstructured":"d\u2019Orsi G, Demaio V, Specchio LM. Pathological gambling plus hypersexuality in restless legs syndrome: a new case. Neurol Sci. 2011;32(4):707\u20139.","journal-title":"Neurol Sci."},{"issue":"4","key":"590_CR16","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/mds.21303","volume":"22","author":"AH Evans","year":"2007","unstructured":"Evans AH, Butzkueven H. Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis. Mov Disord. 2007;22(4):590\u20131.","journal-title":"Mov Disord"},{"issue":"1","key":"590_CR17","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/mds.22309","volume":"24","author":"AH Evans","year":"2009","unstructured":"Evans AH, Stegeman JR. Punding in patients on dopamine agonists for restless leg syndrome. Mov Disord. 2009;24(1):140\u20131.","journal-title":"Mov Disord"},{"key":"590_CR18","doi-asserted-by":"publisher","unstructured":"Jones HB, George S. \u2018You never told me I would turn into a gambler\u2019: a first person account of dopamine agonist\u2013induced gambling addiction in a patient with restless legs syndrome. BMJ Case Rep. 2011;2011. doi: 10.1136\/bcr.07.2011.4459 .","DOI":"10.1136\/bcr.07.2011.4459"},{"issue":"3","key":"590_CR19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0033-3182(10)70695-2","volume":"51","author":"BP Kolla","year":"2010","unstructured":"Kolla BP, Mansukhani MP, Barraza R, Bostwick JM. Impact of dopamine agonists on compulsive behaviors: a case series of pramipexole-induced pathological gambling. Psychosomatics. 2010;51(3):271\u20133.","journal-title":"Psychosomatics."},{"issue":"4","key":"590_CR20","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.sleep.2008.12.010","volume":"10","author":"S Leu-Semenescu","year":"2009","unstructured":"Leu-Semenescu S, Karroum E, Brion A, Konofal E, Arnulf I. Dopamine dysregulation syndrome in a patient with restless legs syndrome. Sleep Med. 2009;10(4):494\u20136.","journal-title":"Sleep Med"},{"issue":"8","key":"590_CR21","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.parkreldis.2006.10.001","volume":"13","author":"J Quickfall","year":"2007","unstructured":"Quickfall J, Suchowersky O. Pathological gambling associated with dopamine agonist use in restless legs syndrome. Parkinsonism Relat Disord. 2007;13(8):535\u20136.","journal-title":"Parkinsonism Relat Disord."},{"issue":"2","key":"590_CR22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.parkreldis.2011.10.010","volume":"18","author":"SR Schreglmann","year":"2012","unstructured":"Schreglmann SR, Gantenbein AR, Eisele G, Baumann CR. Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome. Parkinsonism Relat Disord. 2012;18(2):207\u20139.","journal-title":"Parkinsonism Relat Disord."},{"issue":"4","key":"590_CR23","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1212\/01.wnl.0000252368.25106.b6","volume":"68","author":"M Tippmann-Peikert","year":"2007","unstructured":"Tippmann-Peikert M, Park JG, Boeve BF, Shepard JW, Silber MH. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology. 2007;68(4):301\u20133.","journal-title":"Neurology."},{"issue":"4","key":"590_CR24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.psym.2012.10.002","volume":"54","author":"S Almanzar","year":"2013","unstructured":"Almanzar S, Zapata-Vega MI, Raya JA. Dopamine agonist-induced impulse control disorders in a patient with prolactinoma. Psychosomatics. 2013;54(4):387\u201391.","journal-title":"Psychosomatics."},{"issue":"5","key":"590_CR25","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/WNF.0b013e31829fc165","volume":"36","author":"SK Thondam","year":"2013","unstructured":"Thondam SK, Alusi S, O\u2019Driscoll K, Gilkes CE, Cuthbertson DJ, Daousi C. Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma. Clin Neuropharmacol. 2013;36(5):170\u20132.","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"590_CR26","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1741-6612.2012.00632.x","volume":"31","author":"S Aarons","year":"2012","unstructured":"Aarons S, Peisah C, Wijeratne C. Neuropsychiatric effects of Parkinson\u2019s disease treatment. Australas J Ageing. 2012;31(3):198\u2013202.","journal-title":"Australas J Ageing."},{"issue":"4","key":"590_CR27","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.nrleng.2011.04.010","volume":"29","author":"A Alonso C\u00e1novasa","year":"2014","unstructured":"Alonso C\u00e1novasa A, Luquin Piudo R, Garc\u00eda Ruiz-Espigac P, Burguera JA, Campos Arillo V, Castro A, et al. Dopaminergic agonists in Parkinson\u2019s disease. Neurolog\u00eda (English Edition). 2014;29(4):230\u201341.","journal-title":"Neurolog\u00eda (English Edition)."},{"issue":"2","key":"590_CR28","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1360-0443.2010.03218.x","volume":"106","author":"P Ambermoon","year":"2011","unstructured":"Ambermoon P, Carter A, Hall WD, Dissanayaka NN, O\u2019Sullivan JD. Impulse control disorders in patients with Parkinson\u2019s disease receiving dopamine replacement therapy: evidence and implications for the addictions field. Addiction. 2011;106(2):283\u201393.","journal-title":"Addiction"},{"issue":"1\u20132","key":"590_CR29","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jns.2011.06.006","volume":"310","author":"F Antonelli","year":"2011","unstructured":"Antonelli F, Ray N, Strafella AP. Impulsivity and Parkinson\u2019s disease: more than just disinhibition. J Neurol Sci. 2011;310(1\u20132):202\u20137.","journal-title":"J Neurol Sci"},{"issue":"10","key":"590_CR30","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S1474-4422(09)70225-X","volume":"8","author":"A Antonini","year":"2009","unstructured":"Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH. A reassessment of risks and benefits of dopamine agonists in Parkinson\u2019s disease. Lancet Neurol. 2009;8(10):929\u201337.","journal-title":"Lancet Neurol."},{"issue":"4","key":"590_CR31","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1155\/2013\/579092","volume":"26","author":"S Balarajah","year":"2013","unstructured":"Balarajah S, Cavanna AE. The pathophysiology of impulse control disorders in Parkinson disease. Behav Neurol. 2013;26(4):237\u201344.","journal-title":"Behav Neurol."},{"issue":"4","key":"590_CR32","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1155\/2013\/826742","volume":"27","author":"P Bugalho","year":"2013","unstructured":"Bugalho P, Oliveira-Maia AJ. Impulse control disorders in Parkinson\u2019s disease: crossroads between neurology, psychiatry and neuroscience. Behav Neurol. 2013;27(4):547\u201357.","journal-title":"Behav Neurol."},{"issue":"4","key":"590_CR33","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.baga.2012.08.004","volume":"2","author":"R Cilia","year":"2012","unstructured":"Cilia R. How neurodegeneration, dopamine and maladaptive behavioral learning interact to produce impulse control disorders in Parkinson\u2019s disease. Basal Ganglia. 2012;2(4):195\u20139.","journal-title":"Basal Ganglia."},{"issue":"4","key":"590_CR34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00429-011-0314-0","volume":"216","author":"R Cilia","year":"2011","unstructured":"Cilia R, van Eimeren T. Impulse control disorders in Parkinson\u2019s disease: seeking a roadmap toward a better understanding. Brain Struct Funct. 2011;216(4):289\u201399.","journal-title":"Brain Struct Funct."},{"issue":"4","key":"590_CR35","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.neuron.2009.01.031","volume":"61","author":"A Dagher","year":"2009","unstructured":"Dagher A, Robbins TW. Personality, addiction, dopamine: insights from Parkinson\u2019s disease. Neuron. 2009;61(4):502\u201310.","journal-title":"Neuron"},{"issue":"3","key":"590_CR36","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s10880-012-9302-7","volume":"19","author":"M Delaney","year":"2012","unstructured":"Delaney M, Leroi I, Simpson J, Overton PG. Impulse control disorders in Parkinson\u2019s disease: a psychosocial perspective. J Clin Psychol Med Settings. 2012;19(3):338\u201346.","journal-title":"J Clin Psychol Med Settings"},{"issue":"1\u20132","key":"590_CR37","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jns.2011.07.031","volume":"310","author":"A Djamshidian","year":"2011","unstructured":"Djamshidian A, Averbeck BB, Lees AJ, O\u2019Sullivan SS. Clinical aspects of impulsive compulsive behaviours in Parkinson\u2019s disease. J Neurol Sci. 2011;310(1\u20132):183\u20138.","journal-title":"J Neurol Sci"},{"issue":"11","key":"590_CR38","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1002\/mds.23821","volume":"26","author":"A Djamshidian","year":"2011","unstructured":"Djamshidian A, Cardoso F, Grosset D, Bowden-Jones H, Lees AJ. Pathological gambling in Parkinson\u2019s disease\u2014a review of the literature. Mov Disord. 2011;26(11):1976\u201384.","journal-title":"Mov Disord"},{"issue":"3","key":"590_CR39","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1212\/01.WNL.0000076478.45005.EC","volume":"61","author":"E Driver-Dunckley","year":"2003","unstructured":"Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson\u2019s disease. Neurology. 2003;61(3):422\u20133.","journal-title":"Neurology."},{"issue":"2","key":"590_CR40","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jocn.2010.04.024","volume":"18","author":"A Evans","year":"2011","unstructured":"Evans A. Dopamine agonist-induced substance addiction: the next piece of the puzzle. J Clin Neurosci. 2011;18(2):191\u20132.","journal-title":"J Clin Neurosci."},{"issue":"11","key":"590_CR41","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/mds.22505","volume":"24","author":"AH Evans","year":"2009","unstructured":"Evans AH, Strafella AP, Weintraub D, Stacy M. Impulsive and compulsive behaviors in Parkinson\u2019s disease. Mov Disord. 2009;24(11):1561\u201370.","journal-title":"Mov Disord"},{"issue":"5\u20136","key":"590_CR42","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/FBP.0b013e32833109a0","volume":"20","author":"S Fenu","year":"2009","unstructured":"Fenu S, Wardas J, Morelli M. Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson\u2019s disease. Behav Pharmacol. 2009;20(5\u20136):363\u201379.","journal-title":"Behav Pharmacol"},{"issue":"Suppl 5","key":"590_CR43","doi-asserted-by":"crossref","first-page":"S375","DOI":"10.1007\/s10072-008-1050-y","volume":"29","author":"D Grosset","year":"2008","unstructured":"Grosset D. Dopamine agonists and therapy compliance. Neurol Sci. 2008;29(Suppl 5):S375\u20136.","journal-title":"Neurol Sci."},{"key":"590_CR44","doi-asserted-by":"crossref","unstructured":"Hou J-GG, Lai EC. Non-motor symptoms of Parkinson\u2019s disease. Int J Gerontol. 2007;1(2):53\u201364.","DOI":"10.1016\/S1873-9598(08)70024-3"},{"key":"590_CR45","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.neubiorev.2015.07.010","volume":"56","author":"H Jim\u00e9nez-Urbieta","year":"2015","unstructured":"Jim\u00e9nez-Urbieta H, Gago B, de la Riva P, Delgado-Alvarado M, Marin C, Rodriguez-Oroz MC. Dyskinesias and impulse control disorders in Parkinson\u2019s disease: from pathogenesis to potential therapeutic approaches. Neurosci Biobehav Rev. 2015;56:294\u2013314.","journal-title":"Neurosci Biobehav Rev"},{"issue":"1\u20132","key":"590_CR46","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jns.2011.07.012","volume":"310","author":"R Katzenschlager","year":"2011","unstructured":"Katzenschlager R. Dopaminergic dysregulation syndrome in Parkinson\u2019s disease. J Neurol Sci. 2011;310(1\u20132):271\u20135.","journal-title":"J Neurol Sci"},{"issue":"2","key":"590_CR47","doi-asserted-by":"crossref","first-page":"67","DOI":"10.14802\/jmd.14010","volume":"7","author":"JY Lee","year":"2014","unstructured":"Lee JY, Jeon BS. Maladaptive reward-learning and impulse control disorders in patients with Parkinson\u2019s disease: a clinical overview and pathophysiology update. J Mov Disord. 2014;7(2):67\u201376.","journal-title":"J Mov Disord."},{"key":"590_CR48","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.parkreldis.2016.02.017","volume":"25","author":"S Nakum","year":"2016","unstructured":"Nakum S, Cavanna AE. The prevalence and clinical characteristics of hypersexuality in patients with Parkinson\u2019s disease following dopaminergic therapy: a systematic literature review. Parkinsonism Relat Disord. 2016;25:10\u20136.","journal-title":"Parkinsonism Relat Disord."},{"key":"590_CR49","doi-asserted-by":"crossref","first-page":"728038","DOI":"10.1155\/2014\/728038","volume":"2014","author":"D Pirritano","year":"2014","unstructured":"Pirritano D, Plastino M, Bosco D, Gallelli L, Siniscalchi A, De Sarro G. Gambling disorder during dopamine replacement treatment in Parkinson\u2019s disease: a comprehensive review. Biomed Res Int. 2014;2014:728038.","journal-title":"Biomed Res Int"},{"issue":"11","key":"590_CR50","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1007\/s00415-012-6506-6","volume":"259","author":"M Poletti","year":"2012","unstructured":"Poletti M, Bonuccelli U. Impulse control disorders in Parkinson\u2019s disease: the role of personality and cognitive status. J Neurol. 2012;259(11):2269\u201377.","journal-title":"J Neurol"},{"issue":"2","key":"590_CR51","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/mds.26099","volume":"30","author":"M Samuel","year":"2015","unstructured":"Samuel M, Rodriguez-Oroz M, Antonini A, Brotchie JM, Ray Chaudhuri K, Brown RG, et al. Management of impulse control disorders in Parkinson\u2019s disease: controversies and future approaches. Mov Disord. 2015;30(2):150\u20139.","journal-title":"Mov Disord"},{"issue":"7","key":"590_CR52","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.parkreldis.2013.02.007","volume":"19","author":"G Santangelo","year":"2013","unstructured":"Santangelo G, Barone P, Trojano L, Vitale C. Pathological gambling in Parkinson\u2019s disease. A comprehensive review. Parkinsonism Relat Disord. 2013;19(7):645\u201353.","journal-title":"Parkinsonism Relat Disord."},{"issue":"3","key":"590_CR53","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3233\/JPD-150535","volume":"5","author":"M Sierra","year":"2015","unstructured":"Sierra M, Carnicella S, Strafella AP, Bichon A, Lhomm\u00e9e E, Castrioto A, et al. Apathy and impulse control disorders: yin & yang of dopamine dependent behaviors. J Parkinsons Dis. 2015;5(3):625\u201336.","journal-title":"J Parkinsons Dis."},{"issue":"10","key":"590_CR54","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S1474-4422(05)70177-0","volume":"4","author":"F Stocchi","year":"2005","unstructured":"Stocchi F. Pathological gambling in Parkinson\u2019s disease. Lancet Neurol. 2005;4(10):590\u20132.","journal-title":"Lancet Neurol."},{"issue":"3","key":"590_CR55","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.psychres.2014.12.005","volume":"225","author":"P Tanwani","year":"2015","unstructured":"Tanwani P, Fernie BA, Nik\u010devi\u0107 AV, Spada MM. A systematic review of treatments for impulse control disorders and related behaviours in Parkinson\u2019s disease. Psychiatry Res. 2015;225(3):402\u20136.","journal-title":"Psychiatry Res"},{"issue":"11","key":"590_CR56","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.neurol.2011.01.018","volume":"167","author":"C Villa","year":"2011","unstructured":"Villa C, Pascual-Sedano B, Pagonabarraga J, Kulisevsky J. Impulse control disorders and dopaminergic treatments in Parkinson\u2019s disease. Rev Neurol (Paris). 2011;167(11):827\u201332.","journal-title":"Rev Neurol (Paris)."},{"issue":"12","key":"590_CR57","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S1474-4422(09)70287-X","volume":"8","author":"V Voon","year":"2009","unstructured":"Voon V, Fernagut P-O, Wickens J, Baunez C, Rodriguez M, Pavon N, et al. Chronic dopaminergic stimulation in Parkinson\u2019s disease: from dyskinesias to impulse control disorders. Lancet Neurol. 2009;8(12):1140\u20139.","journal-title":"Lancet Neurol."},{"issue":"4","key":"590_CR58","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/WCO.0b013e32826fbc8f","volume":"20","author":"V Voon","year":"2007","unstructured":"Voon V, Potenza MN, Thomsen T. Medication-related impulse control and repetitive behaviors in Parkinson\u2019s disease. Curr Opin Neurol. 2007;20(4):484\u201392.","journal-title":"Curr Opin Neurol"},{"key":"590_CR59","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.neubiorev.2013.11.001","volume":"38","author":"C Vriend","year":"2014","unstructured":"Vriend C, Pattij T, van der Werf YD, Voorn P, Booij J, Rutten S, et al. Depression and impulse control disorders in Parkinson\u2019s disease: two sides of the same coin? Neurosci Biobehav Rev. 2014;38:60\u201371.","journal-title":"Neurosci Biobehav Rev"},{"issue":"Suppl 2","key":"590_CR60","first-page":"S93","volume":"64","author":"D Weintraub","year":"2008","unstructured":"Weintraub D. Dopamine and impulse control disorders in Parkinson\u2019s disease. Ann Neurol. 2008;64(Suppl 2):S93\u2013100.","journal-title":"Ann Neurol"},{"issue":"2","key":"590_CR61","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/mds.26016","volume":"30","author":"D Weintraub","year":"2015","unstructured":"Weintraub D, David AS, Evans AH, Grant JE, Stacy M. Clinical spectrum of impulse control disorders in Parkinson\u2019s disease. Mov Disord. 2015;30(2):121\u20137.","journal-title":"Mov Disord"},{"issue":"85","key":"590_CR62","first-page":"590","volume":"2009","author":"K Wu","year":"1009","unstructured":"Wu K, Politis M, Piccini P. Parkinson disease and impulse control disorders: a review of clinical features, pathophysiology and management. Postgrad Med J. 1009;2009(85):590\u20136.","journal-title":"Postgrad Med J"},{"issue":"3\u20134","key":"590_CR63","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000114040","volume":"59","author":"R Zand","year":"2008","unstructured":"Zand R. Is dopamine agonist therapy associated with developing pathological gambling in Parkinson\u2019s disease patients? Eur Neurol. 2008;59(3\u20134):183\u20136.","journal-title":"Eur Neurol"},{"issue":"10","key":"590_CR64","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","volume":"62","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006\u201312.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"590_CR65","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0025-6196(11)60538-7","volume":"84","author":"JM Bostwick","year":"2009","unstructured":"Bostwick JM, Hecksel KA, Stevens SR, Bower JH, Ahlskog JE. Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. Mayo Clin Proc. 2009;84(4):310\u20136.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"590_CR66","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.parkreldis.2011.09.007","volume":"18","author":"J Joutsa","year":"2012","unstructured":"Joutsa J, Martikainen K, Vahlberg T, Voon V, Kaasinen V. Impulse control disorders and depression in Finnish patients with Parkinson\u2019s disease. Parkinsonism Relat Disord. 2012;18(2):155\u201360.","journal-title":"Parkinsonism Relat Disord."},{"issue":"15","key":"590_CR67","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov Disord. 2010;25(15):2649\u201353.","journal-title":"Mov Disord"},{"issue":"3","key":"590_CR68","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/mds.25291","volume":"28","author":"J Bastiaens","year":"2013","unstructured":"Bastiaens J, Dorfman BJ, Christos PJ, Nirenberg MJ. Prospective cohort study of impulse control disorders in Parkinson\u2019s disease. Mov Disord. 2013;28(3):327\u201333.","journal-title":"Mov Disord"},{"issue":"1","key":"590_CR69","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.neubiorev.2009.07.007","volume":"34","author":"RJ Holst van","year":"2010","unstructured":"van Holst RJ, van den Brink W, Veltman DJ, Goudriaan AE. Why gamblers fail to win: a review of cognitive and neuroimaging findings in pathological gambling. Neurosci Biobehav Rev. 2010;34(1):87\u2013107.","journal-title":"Neurosci Biobehav Rev"},{"key":"590_CR70","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1471-2377-11-117","volume":"11","author":"V Voon","year":"2011","unstructured":"Voon V, Schoerling A, Wenzel S, Ekanayake V, Reiff J, Trenkwalder C, et al. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC Neurol. 2011;11:117.","journal-title":"BMC Neurol."},{"issue":"5","key":"590_CR71","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/wnf.0b013e31804c780e","volume":"30","author":"ED Driver-Dunckley","year":"2007","unstructured":"Driver-Dunckley ED, Noble BN, Hentz JG, Evidente VG, Caviness JN, Parish J, et al. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol. 2007;30(5):249\u201355.","journal-title":"Clin Neuropharmacol"},{"issue":"10","key":"590_CR72","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.5665\/sleep.3044","volume":"36","author":"S Bayard","year":"2013","unstructured":"Bayard S, Langenier MC, Dauvilliers Y. Decision-making, reward-seeking behaviors and dopamine agonist therapy in restless legs syndrome. Sleep. 2013;36(10):1501\u20137.","journal-title":"Sleep"},{"issue":"5","key":"590_CR73","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/WNF.0b013e3182281b2f","volume":"34","author":"J Martinkova","year":"2011","unstructured":"Martinkova J, Trejbalova L, Sasikova M, Benetin J, Valkovic P. Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clin Neuropharmacol. 2011;34(5):179\u201381.","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"590_CR74","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/cen.12375","volume":"80","author":"I Bancos","year":"2014","unstructured":"Bancos I, Nannenga MR, Bostwick JM, Silber MH, Erickson D, Nippoldt TB. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. Clin Endocrinol (Oxf). 2014;80(6):863\u20138.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"590_CR75","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.pnpbp.2011.02.002","volume":"35","author":"P Solla","year":"2011","unstructured":"Solla P, Cannas A, Floris GL, Orofino G, Costantino E, Boi A, et al. Behavioral, neuropsychiatric and cognitive disorders in Parkinson\u2019s disease patients with and without motor complications. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(4):1009\u201313.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"590_CR76","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.parkreldis.2011.10.005","volume":"18","author":"I Leroi","year":"2012","unstructured":"Leroi I, Andrews M, McDonald K, Harbishettar V, Elliott R, Byrne EJ, et al. Apathy and impulse control disorders in Parkinson\u2019s disease: a direct comparison. Parkinsonism Relat Disord. 2012;18(2):198\u2013203.","journal-title":"Parkinsonism Relat Disord."},{"issue":"3","key":"590_CR77","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3109\/00207454.2011.633722","volume":"122","author":"N Limotai","year":"2012","unstructured":"Limotai N, Oyama G, Go C, Bernal O, Ong T, Moum SJ, et al. Addiction-like manifestations and Parkinson\u2019s disease: a large single center 9-year experience. Int J Neurosci. 2012;122(3):145\u201353.","journal-title":"Int J Neurosci"},{"issue":"7","key":"590_CR78","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3109\/00207454.2013.768243","volume":"123","author":"AQ Rana","year":"2013","unstructured":"Rana AQ, Mansoor W, Hussaini S, Al Mosabbir A, Rahman M, Rahman L. Factors associated with the development of impulse compulsive disorders in Parkinson patients. Int J Neurosci. 2013;123(7):503\u20136.","journal-title":"Int J Neurosci"},{"issue":"2","key":"590_CR79","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/jnp.12026","volume":"7","author":"I Leroi","year":"2013","unstructured":"Leroi I, Barraclough M, McKie S, Hinvest N, Evans J, Elliott R, et al. Dopaminergic influences on executive function and impulsive behaviour in impulse control disorders in Parkinson\u2019s disease. J Neuropsychol. 2013;7(2):306\u201325.","journal-title":"J Neuropsychol."},{"issue":"1","key":"590_CR80","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.parkreldis.2013.09.006","volume":"20","author":"MB Callesen","year":"2014","unstructured":"Callesen MB, Weintraub D, Damholdt MF, M\u00f8ller A. Impulsive and compulsive behaviors among Danish patients with Parkinson\u2019s disease: prevalence, depression, and personality. Parkinsonism Relat Disord. 2014;20(1):22\u20136.","journal-title":"Parkinsonism Relat Disord."},{"issue":"4","key":"590_CR81","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3233\/JPD-140366","volume":"4","author":"J Sachdeva","year":"2014","unstructured":"Sachdeva J, Harbishettar V, Barraclough M, McDonald K, Leroi I. Clinical profile of compulsive sexual behaviour and paraphilia in Parkinson\u2019s disease. J Parkinsons Dis. 2014;4(4):665\u201370.","journal-title":"J Parkinsons Dis."},{"issue":"1","key":"590_CR82","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.euroneuro.2014.11.006","volume":"25","author":"FE Pontieri","year":"2015","unstructured":"Pontieri FE, Assogna F, Pellicano C, Cacciari C, Pannunzi S, Morrone A, et al. Sociodemographic, neuropsychiatric and cognitive characteristics of pathological gambling and impulse control disorders NOS in Parkinson\u2019s disease. Eur Neuropsychopharmacol. 2015;25(1):69\u201376.","journal-title":"Eur Neuropsychopharmacol"},{"key":"590_CR83","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.parkreldis.2016.06.005","volume":"30","author":"S Krishnamoorthy","year":"2016","unstructured":"Krishnamoorthy S, Rajan R, Banerjee M, Kumar H, Sarma G, Krishnan S, et al. Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson\u2019s disease patients. Parkinsonism Relat Disord. 2016;30:13\u20137.","journal-title":"Parkinsonism Relat Disord."},{"issue":"5","key":"590_CR84","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","volume":"67","author":"D Weintraub","year":"2010","unstructured":"Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589\u201395.","journal-title":"Arch Neurol"},{"issue":"7","key":"590_CR85","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1212\/01.wnl.0000238401.76928.45","volume":"67","author":"G Pontone","year":"2006","unstructured":"Pontone G, Williams JR, Bassett SS, Marsh L. Clinical features associated with impulse control disorders in Parkinson disease. Neurology. 2006;67(7):1258\u201361.","journal-title":"Neurology."},{"issue":"7","key":"590_CR86","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/archneur.63.7.969","volume":"63","author":"D Weintraub","year":"2006","unstructured":"Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH, Duda JE, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006;63(7):969\u201373.","journal-title":"Arch Neurol"},{"issue":"4","key":"590_CR87","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10899-008-9099-3","volume":"24","author":"D Crockford","year":"2008","unstructured":"Crockford D, Quickfall J, Currie S, Furtado S, Suchowersky O, El-Guebaly N. Prevalence of problem and pathological gambling in Parkinson\u2019s disease. J Gambl Stud. 2008;24(4):411\u201322.","journal-title":"J Gambl Stud"},{"issue":"1","key":"590_CR88","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.neulet.2009.06.074","volume":"465","author":"W Fan","year":"2009","unstructured":"Fan W, Ding H, Ma J, Chan P. Impulse control disorders in Parkinson\u2019s disease in a Chinese population. Neurosci Lett. 2009;465(1):6\u20139.","journal-title":"Neurosci Lett"},{"issue":"Pt 2","key":"590_CR89","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/brain\/aws326","volume":"136","author":"M Politis","year":"2013","unstructured":"Politis M, Loane C, Wu K, O\u2019Sullivan SS, Woodhead Z, Kiferle L, et al. Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson\u2019s disease. Brain. 2013;136(Pt 2):400\u201311.","journal-title":"Brain"},{"issue":"7","key":"590_CR90","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.parkreldis.2013.03.004","volume":"19","author":"GT Valen\u00e7a","year":"2013","unstructured":"Valen\u00e7a GT, Glass PG, Negreiros NN, Duarte MB, Ventura LM, Mueller M, et al. Past smoking and current dopamine agonist use show an independent and dose-dependent association with impulse control disorders in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2013;19(7):698\u2013700.","journal-title":"Parkinsonism Relat Disord."},{"issue":"12","key":"590_CR91","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/jamainternmed.2014.5262","volume":"174","author":"TJ Moore","year":"2014","unstructured":"Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med. 2014;174(12):1930\u20133.","journal-title":"JAMA Intern Med."},{"issue":"8","key":"590_CR92","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/jnnp-2013-306787","volume":"85","author":"PJ Garcia-Ruiz","year":"2014","unstructured":"Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, Herranz Barcenas A, Vela L, Sanchez Alonso P, et al. Impulse control disorder in patients with Parkinson\u2019s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85(8):840\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"590_CR93","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.parkreldis.2014.05.014","volume":"20","author":"M Rodr\u00edguez-Violante","year":"2014","unstructured":"Rodr\u00edguez-Violante M, Gonz\u00e1lez-Latapi P, Cervantes-Arriaga A, Camacho-Ordo\u00f1ez A, Weintraub D. Impulse control and related disorders in Mexican Parkinson\u2019s disease patients. Parkinsonism Relat Disord. 2014;20(8):907\u201310.","journal-title":"Parkinsonism Relat Disord."},{"issue":"4","key":"590_CR94","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.nrleng.2015.05.008","volume":"31","author":"N S\u00e1ez-Franc\u00e0s","year":"2016","unstructured":"S\u00e1ez-Franc\u00e0s N, Mart\u00ed Andr\u00e8s G, Ram\u00edrez N, de F\u00e0bregues O, \u00c1lvarez-Sab\u00edn J, Casas M, et al. Clinical and psychopathological factors associated with impulse control disorders in Parkinson\u2019s disease. Neurolog\u00eda (English Edition). 2016;31(4):231\u20138.","journal-title":"Neurolog\u00eda (English Edition)."},{"key":"590_CR95","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jns.2016.07.003","volume":"368","author":"L Vela","year":"2016","unstructured":"Vela L, Mart\u00ednez Castrillo JC, Garc\u00eda Ruiz P, Gasca-Salas C, Mac\u00edas Mac\u00edas Y, P\u00e9rez Fern\u00e1ndez E, et al. The high prevalence of impulse control behaviors in patients with early-onset Parkinson\u2019s disease: a cross-sectional multicenter study. J Neurol Sci. 2016;368:150\u20134.","journal-title":"J Neurol Sci"},{"issue":"2","key":"590_CR96","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/WNF.0000000000000202","volume":"40","author":"CC Ramirez G\u00f3mez","year":"2017","unstructured":"Ramirez G\u00f3mez CC, Serrano Due\u00f1as M, Bernal O, Araoz N, S\u00e1enz Farret M, Aldinio V, et al. A multicenter comparative study of impulse control disorder in Latin American patients with Parkinson disease. Clin Neuropharmacol. 2017;40(2):51\u20135.","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"590_CR97","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/JCP.0b013e3182979830","volume":"33","author":"M Poletti","year":"2013","unstructured":"Poletti M, Logi C, Lucetti C, Del Dotto P, Baldacci F, Vergallo A, et al. A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs. J Clin Psychopharmacol. 2013;33(5):691\u20134.","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"590_CR98","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/mds.21110","volume":"21","author":"KA Grosset","year":"2006","unstructured":"Grosset KA, Macphee G, Pal G, Stewart D, Watt A, Davie J, et al. Problematic gambling on dopamine agonists: not such a rarity. Mov Disord. 2006;21(12):2206\u20138.","journal-title":"Mov Disord"},{"issue":"5","key":"590_CR99","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/hbm.21067","volume":"32","author":"Z Ye","year":"2011","unstructured":"Ye Z, Hammer A, Camara E, Munte TF. Pramipexole modulates the neural network of reward anticipation. Hum Brain Mapp. 2011;32(5):800\u201311.","journal-title":"Hum Brain Mapp"},{"issue":"10","key":"590_CR100","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.parkreldis.2012.06.005","volume":"18","author":"J Joutsa","year":"2012","unstructured":"Joutsa J, Martikainen K, Vahlberg T, Kaasinen V. Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2012;18(10):1079\u201383.","journal-title":"Parkinsonism Relat Disord."},{"issue":"3","key":"590_CR101","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/NRL.0b013e31819f952b","volume":"16","author":"G Kenangil","year":"2010","unstructured":"Kenangil G, Ozekmekci S, Sohtaoglu M, Erginoz E. Compulsive behaviors in patients with Parkinson\u2019s disease. Neurologist. 2010;16(3):192\u20135.","journal-title":"Neurologist."},{"issue":"3","key":"590_CR102","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.parkreldis.2009.12.002","volume":"16","author":"J-Y Lee","year":"2010","unstructured":"Lee J-Y, Kim J-M, Kim JW, Cho J, Lee WY, Kim H-J, et al. Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disord. 2010;16(3):202\u20137.","journal-title":"Parkinsonism Relat Disord."},{"issue":"6","key":"590_CR103","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/WNF.0b013e31826e6e6d","volume":"35","author":"S Perez-Lloret","year":"2012","unstructured":"Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Brefel-Courbon C, et al. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin Neuropharmacol. 2012;35(6):261\u20135.","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"590_CR104","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.parkreldis.2010.02.006","volume":"16","author":"M Sohtaoglu","year":"2010","unstructured":"Sohtaoglu M, Demiray DY, Kenangil G, Ozekmekci S, Erginoz E. Long term follow-up of Parkinson\u2019s disease patients with impulse control disorders. Parkinsonism Relat Disord. 2010;16(5):334\u20137.","journal-title":"Parkinsonism Relat Disord."},{"issue":"5","key":"590_CR105","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/0269881106073109","volume":"21","author":"N Giladi","year":"2007","unstructured":"Giladi N, Weitzman N, Schreiber S, Shabtai H, Peretz C. New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson\u2019s disease: the role of dopamine agonist treatment and age at motor symptoms onset. J Psychopharmacol. 2007;21(5):501\u20136.","journal-title":"J Psychopharmacol."},{"issue":"4","key":"590_CR106","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.parkreldis.2011.01.009","volume":"17","author":"A Hassan","year":"2011","unstructured":"Hassan A, Bower JH, Kumar N, Matsumoto JY, Fealey RD, Josephs KA, et al. Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies. Parkinsonism Relat Disord. 2011;17(4):260\u20134.","journal-title":"Parkinsonism Relat Disord."},{"issue":"10","key":"590_CR107","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/ene.13078","volume":"23","author":"A Antonini","year":"2016","unstructured":"Antonini A, Chaudhuri KR, Boroojerdi B, Asgharnejad M, Bauer L, Grieger F, et al. Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis. Eur J Neurol. 2016;23(10):1556\u201365.","journal-title":"Eur J Neurol"},{"issue":"4","key":"590_CR108","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/WNF.0000000000000091","volume":"38","author":"A Todorova","year":"2015","unstructured":"Todorova A, Samuel M, Brown RG, Chaudhuri KR. Infusion therapies and development of impulse control disorders in advanced Parkinson disease: clinical experience after 3\u00a0years\u2019 follow-up. Clin Neuropharmacol. 2015;38(4):132\u20134.","journal-title":"Clin Neuropharmacol"},{"issue":"Pt 9","key":"590_CR109","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1093\/brain\/awp170","volume":"132","author":"B Abler","year":"2009","unstructured":"Abler B, Hahlbrock R, Unrath A, Gron G, Kassubek J. At-risk for pathological gambling: imaging neural reward processing under chronic dopamine agonists. Brain. 2009;132(Pt 9):2396\u2013402.","journal-title":"Brain"},{"issue":"13","key":"590_CR110","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1038\/npp.2009.124","volume":"34","author":"T Eimeren van","year":"2009","unstructured":"van Eimeren T, Ballanger B, Pellecchia G, Miyasaki JM, Lang AE, Strafella AP. Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson\u2019s disease? Neuropsychopharmacology. 2009;34(13):2758\u201366.","journal-title":"Neuropsychopharmacology."},{"issue":"19","key":"590_CR111","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1212\/WNL.0b013e3181fc27fa","volume":"75","author":"T Eimeren van","year":"2010","unstructured":"van Eimeren T, Pellecchia G, Cilia R, Ballanger B, Steeves TD, Houle S, et al. Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. Neurology. 2010;75(19):1711\u20136.","journal-title":"Neurology."},{"issue":"4","key":"590_CR112","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00213-009-1697-y","volume":"207","author":"V Voon","year":"2010","unstructured":"Voon V, Reynolds B, Brezing C, Gallea C, Skaljic M, Ekanayake V, et al. Impulsive choice and response in dopamine agonist-related impulse control behaviors. Psychopharmacology. 2010;207(4):645\u201359.","journal-title":"Psychopharmacology"},{"issue":"12","key":"590_CR113","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1177\/0269881114548437","volume":"28","author":"A Djamshidian","year":"2014","unstructured":"Djamshidian A, O\u2019Sullivan SS, Lawrence AD, Foltynie T, Aviles-Olmos I, Magdalinou N, et al. Perceptual decision-making in patients with Parkinson\u2019s disease. J Psychopharmacol. 2014;28(12):1149\u201354.","journal-title":"J Psychopharmacol."},{"issue":"Pt 5","key":"590_CR114","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1093\/brain\/awr080","volume":"134","author":"V Voon","year":"2011","unstructured":"Voon V, Gao J, Brezing C, Symmonds M, Ekanayake V, Fernandez H, et al. Dopamine agonists and risk: impulse control disorders in Parkinson\u2019s disease. Brain. 2011;134(Pt 5):1438\u201346.","journal-title":"Brain"},{"issue":"4","key":"590_CR115","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1037\/a0023795","volume":"125","author":"DO Claassen","year":"2011","unstructured":"Claassen DO, van den Wildenberg WP, Ridderinkhof KR, Jessup CK, Harrison MB, Wooten GF, et al. The risky business of dopamine agonists in Parkinson disease and impulse control disorders. Behav Neurosci. 2011;125(4):492\u2013500.","journal-title":"Behav Neurosci"},{"key":"590_CR116","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pbb.2014.11.017","volume":"129","author":"DO Claassen","year":"2015","unstructured":"Claassen DO, van den Wildenberg WP, Harrison MB, van Wouwe NC, Kanoff K, Neimat JS, et al. Proficient motor impulse control in Parkinson disease patients with impulsive and compulsive behaviors. Pharmacol Biochem Behav. 2015;129:19\u201325.","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"590_CR117","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.parkreldis.2011.08.016","volume":"18","author":"P Shotbolt","year":"2012","unstructured":"Shotbolt P, Moriarty J, Costello A, Jha A, David A, Ashkan K, et al. Relationships between deep brain stimulation and impulse control disorders in Parkinson\u2019s disease, with a literature review. Parkinsonism Relat Disord. 2012;18(1):10\u20136.","journal-title":"Parkinsonism Relat Disord."},{"issue":"4","key":"590_CR118","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.parkreldis.2011.10.019","volume":"18","author":"A Vallelunga","year":"2012","unstructured":"Vallelunga A, Flaibani R, Formento-Dojot P, Biundo R, Facchini S, Antonini A. Role of genetic polymorphisms of the dopaminergic system in Parkinson\u2019s disease patients with impulse control disorders. Parkinsonism Relat Disord. 2012;18(4):397\u20139.","journal-title":"Parkinsonism Relat Disord."},{"issue":"2","key":"590_CR119","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00415-012-6645-9","volume":"260","author":"J Kim","year":"2013","unstructured":"Kim J, Kim M, Kwon DY, Seo WK, Kim JH, Baik JS, et al. Clinical characteristics of impulse control and repetitive behavior disorders in Parkinson\u2019s disease. J Neurol. 2013;260(2):429\u201337.","journal-title":"J Neurol"},{"issue":"3","key":"590_CR120","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s10899-014-9503-0","volume":"31","author":"J Olley","year":"2015","unstructured":"Olley J, Blaszczynski A, Lewis S. Dopaminergic medication in Parkinson\u2019s disease and problem gambling. J Gambl Stud. 2015;31(3):1085\u2013106.","journal-title":"J Gambl Stud"},{"issue":"3","key":"590_CR121","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/j.clinph.2015.11.233","volume":"127","author":"T Gescheidt","year":"2016","unstructured":"Gescheidt T, Majerov\u00e1 V, Men\u0161\u00edkov\u00e1 K, Du\u0161ek L, Czek\u00f3ov\u00e1 K, Kotkov\u00e1 P, et al. ID 16-Impulse control disorders in young-onset patients with Parkinson\u2019s disease: Cross-sectional study seeking associated factors with regard of personal characteristics. Clin Neurophysiol. 2016;127(3):e70.","journal-title":"Clin Neurophysiol"},{"issue":"6","key":"590_CR122","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/ana.22356","volume":"69","author":"V Voon","year":"2011","unstructured":"Voon V, Sohr M, Lang AE, Potenza MN, Siderowf AD, Whetteckey J, et al. Impulse control disorders in Parkinson disease: a multicenter case\u2013control study. Ann Neurol. 2011;69(6):986\u201396.","journal-title":"Ann Neurol"},{"issue":"1\u20132","key":"590_CR123","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jns.2009.11.010","volume":"290","author":"E Pourcher","year":"2010","unstructured":"Pourcher E, Remillard S, Cohen H. Compulsive habits in restless legs syndrome patients under dopaminergic treatment. J Neurol Sci. 2010;290(1\u20132):52\u20136.","journal-title":"J Neurol Sci"},{"key":"590_CR124","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jns.2016.03.032","volume":"366","author":"L Brusa","year":"2016","unstructured":"Brusa L, Pavino V, Massimetti MC, Ceravolo R, Stefani S, Stanzione P. Pathological gambling in Parkinson\u2019s disease patients: dopaminergic medication or personality traits fault? J Neurol Sci. 2016;366:167\u201370.","journal-title":"J Neurol Sci"},{"key":"590_CR125","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.parkreldis.2016.05.017","volume":"29","author":"R Cilia","year":"2016","unstructured":"Cilia R, Benfante R, Asselta R, Marabini L, Cereda E, Siri C, et al. Tryptophan hydroxylase type 2 variants modulate severity and outcome of addictive behaviors in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2016;29:96\u2013103.","journal-title":"Parkinsonism Relat Disord."},{"key":"590_CR126","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12883-015-0316-2","volume":"15","author":"S Zainal Abidin","year":"2015","unstructured":"Zainal Abidin S, Tan EL, Chan SC, Jaafar A, Lee AX, Abd Hamid MH, et al. DRD and GRIN2B polymorphisms and their association with the development of impulse control behaviour among Malaysian Parkinson\u2019s disease patients. BMC Neurol. 2015;15:59.","journal-title":"BMC Neurol."},{"issue":"10","key":"590_CR127","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/jnnp-2015-312848","volume":"87","author":"J Kraemmer","year":"2016","unstructured":"Kraemmer J, Smith K, Weintraub D, Guillemot V, Nalls MA, Cormier-Dequaire F, et al. Clinical-genetic model predicts incident impulse control disorders in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2016;87(10):1106\u201311.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"590_CR128","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.nbd.2010.03.013","volume":"39","author":"R Cilia","year":"2010","unstructured":"Cilia R, Ko JH, Cho SS, van Eimeren T, Marotta G, Pellecchia G, et al. Reduced dopamine transporter density in the ventral striatum of patients with Parkinson\u2019s disease and pathological gambling. Neurobiol Dis. 2010;39(1):98\u2013104.","journal-title":"Neurobiol Dis"},{"issue":"8","key":"590_CR129","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1136\/jnnp-2015-311827","volume":"87","author":"KM Smith","year":"2016","unstructured":"Smith KM, Xie SX, Weintraub D. Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease. J Neurol Neurosurg Psychiatry. 2016;87(8):864\u201370.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"590_CR130","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.parkreldis.2016.05.028","volume":"30","author":"E Premi","year":"2016","unstructured":"Premi E, Pilotto A, Garibotto V, Bigni B, Turrone R, Alberici A, et al. Impulse control disorder in PD: A lateralized monoaminergic frontostriatal disconnection syndrome? Parkinsonism Relat Disord. 2016;30:62\u20136.","journal-title":"Parkinsonism Relat Disord."},{"issue":"Pt 4","key":"590_CR131","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/brain\/awr003","volume":"134","author":"SS O\u2019Sullivan","year":"2011","unstructured":"O\u2019Sullivan SS, Wu K, Politis M, Lawrence AD, Evans AH, Bose SK, et al. Cue-induced striatal dopamine release in Parkinson\u2019s disease-associated impulsive-compulsive behaviours. Brain. 2011;134(Pt 4):969\u201378.","journal-title":"Brain"},{"issue":"3","key":"590_CR132","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.nbd.2012.06.021","volume":"48","author":"NJ Ray","year":"2012","unstructured":"Ray NJ, Miyasaki JM, Zurowski M, Ko JH, Cho SS, Pellecchia G, et al. Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson\u2019s patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study. Neurobiol Dis. 2012;48(3):519\u201325.","journal-title":"Neurobiol Dis"},{"issue":"2","key":"590_CR133","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/mds.26135","volume":"30","author":"DE Payer","year":"2015","unstructured":"Payer DE, Guttman M, Kish SJ, Tong J, Strafella A, Zack M, et al. [(1)(1)C]-(+)-PHNO PET imaging of dopamine D(2\/3) receptors in Parkinson\u2019s disease with impulse control disorders. Mov Disord. 2015;30(2):160\u20136.","journal-title":"Mov Disord"},{"key":"590_CR134","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.parkreldis.2015.10.013","volume":"24","author":"A Tessitore","year":"2016","unstructured":"Tessitore A, Santangelo G, De Micco R, Vitale C, Giordano A, Raimo S, et al. Cortical thickness changes in patients with Parkinson\u2019s disease and impulse control disorders. Parkinsonism Relat Disord. 2016;24:119\u201325.","journal-title":"Parkinsonism Relat Disord."},{"issue":"7","key":"590_CR135","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jocn.2012.07.020","volume":"20","author":"YE Kim","year":"2013","unstructured":"Kim YE, Kim HJ, Kim H-J, Lee J-Y, Yun JY, Kim J-Y, et al. Impulse control and related behaviors after bilateral subthalamic stimulation in patients with Parkinson\u2019s disease. J Clin Neurosci. 2013;20(7):964\u20139.","journal-title":"J Clin Neurosci."},{"issue":"8","key":"590_CR136","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.parkreldis.2011.06.001","volume":"17","author":"M Auyeung","year":"2011","unstructured":"Auyeung M, Tsoi TH, Tang WK, Cheung CM, Lee CN, Li R, et al. Impulse control disorders in Chinese Parkinson\u2019s disease patients: the effect of ergot derived dopamine agonist. Parkinsonism Relat Disord. 2011;17(8):635\u20137.","journal-title":"Parkinsonism Relat Disord."},{"issue":"10","key":"590_CR137","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.parkreldis.2011.07.009","volume":"17","author":"S-Y Lim","year":"2011","unstructured":"Lim S-Y, Tan ZK, Ngam PI, Lor TL, Mohamed H, Schee JP, et al. Impulsive-compulsive behaviors are common in Asian Parkinson\u2019s disease patients: assessment using the QUIP. Parkinsonism Relat Disord. 2011;17(10):761\u20134.","journal-title":"Parkinsonism Relat Disord."},{"issue":"1","key":"590_CR138","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/WNN.0000000000000047","volume":"28","author":"E Harris","year":"2015","unstructured":"Harris E, McNamara P, Durso R. Novelty seeking in patients with right- versus left-onset Parkinson disease. Cogn Behav Neurol. 2015;28(1):11\u20136.","journal-title":"Cogn Behav Neurol."},{"issue":"11","key":"590_CR139","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.parkreldis.2015.09.026","volume":"21","author":"M Al-Khaled","year":"2015","unstructured":"Al-Khaled M, Heldmann M, Bolstorff I, Hagenah J, M\u00fcnte TF. Intertemporal choice in Parkinson\u2019s disease and restless legs syndrome. Parkinsonism Relat Disord. 2015;21(11):1330\u20135.","journal-title":"Parkinsonism Relat Disord."},{"issue":"4","key":"590_CR140","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1016\/j.neuroimage.2011.11.073","volume":"59","author":"E Aarts","year":"2012","unstructured":"Aarts E, Helmich RC, Janssen MJR, Oyen WJG, Bloem BR, Cools R. Aberrant reward processing in Parkinson\u2019s disease is associated with dopamine cell loss. NeuroImage. 2012;59(4):3339\u201346.","journal-title":"NeuroImage."},{"issue":"3","key":"590_CR141","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S1474-4422(17)30004-2","volume":"16","author":"V Voon","year":"2017","unstructured":"Voon V, Napier TC, Frank MJ, Sgambato-Faure V, Grace AA, Rodriguez-Oroz M, et al. Impulse control disorders and levodopa-induced dyskinesias in Parkinson\u2019s disease: an update. Lancet Neurol. 2017;16(3):238\u201350.","journal-title":"Lancet Neurol."},{"issue":"6","key":"590_CR142","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/hbm.22344","volume":"35","author":"F Antonelli","year":"2014","unstructured":"Antonelli F, Ko JH, Miyasaki J, Lang AE, Houle S, Valzania F, et al. Dopamine-agonists and impulsivity in Parkinson\u2019s disease: impulsive choices vs. impulsive actions. Hum Brain Mapp. 2014;35(6):2499\u2013506.","journal-title":"Hum Brain Mapp"},{"issue":"7","key":"590_CR143","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1212\/WNL.0b013e3182a2935a","volume":"81","author":"C O\u2019Callaghan","year":"2013","unstructured":"O\u2019Callaghan C, Hornberger M. Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology. 2013;81(7):694\u20135.","journal-title":"Neurology."},{"key":"590_CR144","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4137\/JCNSD.S5210","volume":"3","author":"PS Fishman","year":"2011","unstructured":"Fishman PS. Pramipexole and its extended release formulation for Parkinson\u2019s disease. J Cent Nerv Syst Dis. 2011;3:169\u201378.","journal-title":"J Cent Nerv Syst Dis."},{"issue":"14","key":"590_CR145","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1080\/14656566.2016.1219337","volume":"17","author":"F Stocchi","year":"2016","unstructured":"Stocchi F, Torti M, Fossati C. Advances in dopamine receptor agonists for the treatment of Parkinson\u2019s disease. Expert Opin Pharmacother. 2016;17(14):1889\u2013902.","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"590_CR146","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/ene.13034","volume":"23","author":"A Rizos","year":"2016","unstructured":"Rizos A, Sauerbier A, Antonini A, Weintraub D, Martinez-Martin P, Kessel B, et al. A European multicentre survey of impulse control behaviours in Parkinson\u2019s disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol. 2016;23(8):1255\u201361.","journal-title":"Eur J Neurol"},{"issue":"2","key":"590_CR147","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1212\/WNL.0b013e31827b915c","volume":"80","author":"D Weintraub","year":"2013","unstructured":"Weintraub D, Papay K, Siderowf A. Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology. 2013;80(2):176\u201380.","journal-title":"Neurology."},{"issue":"3","key":"590_CR148","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/mds.23501","volume":"26","author":"A Antonini","year":"2011","unstructured":"Antonini A, Siri C, Santangelo G, Cilia R, Poletti M, Canesi M, et al. Impulsivity and compulsivity in drug-naive patients with Parkinson\u2019s disease. Mov Disord. 2011;26(3):464\u20138.","journal-title":"Mov Disord"},{"issue":"3","key":"590_CR149","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.addbeh.2013.11.005","volume":"39","author":"L Gaboriau","year":"2014","unstructured":"Gaboriau L, Victorri-Vigneau C, Gerardin M, Allain-Veyrac G, Jolliet-Evin P, Grall-Bronnec M. Aripiprazole: a new risk factor for pathological gambling? A report of 8 case reports. Addict Behav. 2014;39(3):562\u20135.","journal-title":"Addict Behav"},{"issue":"1","key":"590_CR150","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10899-013-9433-2","volume":"31","author":"P Grotsch","year":"2015","unstructured":"Grotsch P, Lange C, Wiesbeck GA, Lang U. Pathological gambling induced by dopamine antagonists: a case report. J Gambl Stud. 2015;31(1):295\u20137.","journal-title":"J Gambl Stud"},{"issue":"3","key":"590_CR151","doi-asserted-by":"crossref","first-page":"160","DOI":"10.12968\/hmed.2013.74.3.160","volume":"74","author":"GJ Macphee","year":"2013","unstructured":"Macphee GJ, Chaudhuri KR, David AS, Worth P, Wood B. Managing impulse control behaviours in Parkinson\u2019s disease: practical guidelines. Br J Hosp Med (Lond). 2013;74(3):160\u20136.","journal-title":"Br J Hosp Med (Lond)."},{"issue":"1","key":"590_CR152","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/WNF.0b013e3181b7926f","volume":"33","author":"KE Lyons","year":"2010","unstructured":"Lyons KE, Friedman JH, Hermanowicz N, Isaacson SH, Hauser RA, Hersh BP, et al. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects. Clin Neuropharmacol. 2010;33(1):5\u201310.","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"590_CR153","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000337442","volume":"18","author":"S Jimenez-Murcia","year":"2012","unstructured":"Jimenez-Murcia S, Bove FI, Israel M, Steiger H, Fernandez-Aranda F, Alvarez-Moya E, et al. Cognitive-behavioral therapy for pathological gambling in Parkinson\u2019s disease: a pilot controlled study. Eur Addict Res. 2012;18(6):265\u201374.","journal-title":"Eur Addict Res"},{"issue":"6","key":"590_CR154","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.parkreldis.2006.07.011","volume":"13","author":"F Bandini","year":"2007","unstructured":"Bandini F, Primavera A, Pizzorno M, Cocito L. Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2007;13(6):369\u201371.","journal-title":"Parkinsonism Relat Disord."},{"issue":"6","key":"590_CR155","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.parkreldis.2011.02.013","volume":"17","author":"M Broen","year":"2018","unstructured":"Broen M, Duits A, Visser-Vandewalle V, Temel Y, Winogrodzka A. Impulse control and related disorders in Parkinson\u2019s disease patients treated with bilateral subthalamic nucleus stimulation: a review. Parkinsonism Relat Disord. 2018;17(6):413\u20137.","journal-title":"Parkinsonism Relat Disord."},{"issue":"5","key":"590_CR156","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.parkreldis.2007.11.008","volume":"14","author":"PE Bermejo","year":"2008","unstructured":"Bermejo PE. Topiramate in managing impulse control disorders in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2008;14(5):448\u20139.","journal-title":"Parkinsonism Relat Disord."},{"issue":"5","key":"590_CR157","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.parkreldis.2011.03.003","volume":"17","author":"CW Hicks","year":"2011","unstructured":"Hicks CW, Pandya MM, Itin I, Fernandez HH. Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson\u2019s disease. Parkinsonism Relat Disord. 2011;17(5):379\u201381.","journal-title":"Parkinsonism Relat Disord."},{"issue":"10","key":"590_CR158","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1007\/s00415-010-5603-7","volume":"257","author":"PE Bermejo","year":"2010","unstructured":"Bermejo PE, Ruiz-Huete C, Anciones B. Zonisamide in managing impulse control disorders in Parkinson\u2019s disease. J Neurol. 2010;257(10):1682\u20135.","journal-title":"J Neurol"},{"issue":"3","key":"590_CR159","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/WNF.0b013e31824d529b","volume":"35","author":"D Bosco","year":"2012","unstructured":"Bosco D, Plastino M, Colica C, Bosco F, Arianna S, Vecchio A, et al. Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease. Clin Neuropharmacol. 2012;35(3):118\u201320.","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"590_CR160","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/mds.10625","volume":"19","author":"R Kurlan","year":"2004","unstructured":"Kurlan R. Disabling repetitive behaviors in Parkinson\u2019s disease. Mov Disord. 2004;19(4):433\u20137.","journal-title":"Mov Disord"},{"issue":"1","key":"590_CR161","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/JCP.0b013e31802e98c3","volume":"27","author":"L Sevincok","year":"2007","unstructured":"Sevincok L, Akoglu A, Akyol A. Quetiapine in a case with Parkinson disease and pathological gambling. J Clin Psychopharmacol. 2007;27(1):107\u20138.","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"590_CR162","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/mds.23177","volume":"25","author":"A Rotondo","year":"2010","unstructured":"Rotondo A, Bosco D, Plastino M, Consoli A, Bosco F. Clozapine for medication-related pathological gambling in Parkinson disease. Mov Disord. 2010;25(12):1994\u20135.","journal-title":"Mov Disord"},{"issue":"6","key":"590_CR163","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.parkreldis.2010.02.011","volume":"16","author":"S Pallanti","year":"2010","unstructured":"Pallanti S, Bernardi S, Raglione LM, Marini P, Ammannati F, Sorbi S, et al. Complex repetitive behavior: Punding after bilateral subthalamic nucleus stimulation in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2010;16(6):376\u201380.","journal-title":"Parkinsonism Relat Disord."},{"issue":"1","key":"590_CR164","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1176\/appi.neuropsych.23.1.56","volume":"23","author":"LB Zahodne","year":"2011","unstructured":"Zahodne LB, Susatia F, Bowers D, Ong TL, Jacobson CE 4th, Okun MS, et al. Binge eating in Parkinson\u2019s disease: prevalence, correlates and the contribution of deep brain stimulation. J Neuropsychiatry Clin Neurosci. 2011;23(1):56\u201362.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"10","key":"590_CR165","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.sleep.2012.08.004","volume":"13","author":"MC Lipford","year":"2012","unstructured":"Lipford MC, Silber MH. Long-term use of pramipexole in the management of restless legs syndrome. Sleep Med. 2012;13(10):1280\u20135.","journal-title":"Sleep Med"},{"key":"590_CR166","doi-asserted-by":"crossref","unstructured":"Patel S, Garcia X, Mohammad ME, Yu XX, Vlastaris K, O\u2019Donnell K, et al. Dopamine agonist withdrawal syndrome (DAWS) in a tertiary Parkinson disease treatment center. J Neurol Sci. 2017;379(Aug):308\u201311.","DOI":"10.1016\/j.jns.2017.06.022"},{"issue":"1\u20132","key":"590_CR167","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jns.2011.05.044","volume":"310","author":"A \u00c1vila","year":"2011","unstructured":"\u00c1vila A, Cardona X, Mart\u00edn-Baranera M, Bello J, Sastre F. Impulsive and compulsive behaviors in Parkinson\u2019s disease: a one-year follow-up study. J Neurol Sci. 2011;310(1\u20132):197\u2013201.","journal-title":"J Neurol Sci"},{"issue":"1\u20132","key":"590_CR168","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jns.2011.08.001","volume":"310","author":"R Biundo","year":"2011","unstructured":"Biundo R, Formento-Dojot P, Facchini S, Vallelunga A, Ghezzo L, Foscolo L, et al. Brain volume changes in Parkinson\u2019s disease and their relationship with cognitive and behavioural abnormalities. J Neurol Sci. 2011;310(1\u20132):64\u20139.","journal-title":"J Neurol Sci"},{"issue":"13","key":"590_CR169","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1016\/j.neuropsychologia.2013.08.008","volume":"51","author":"ME Sharp","year":"2013","unstructured":"Sharp ME, Viswanathan J, McKeown MJ, Appel-Cresswell S, Stoessl AJ, Barton JJS. Decisions under risk in Parkinson\u2019s disease: preserved evaluation of probability and magnitude. Neuropsychologia. 2013;51(13):2679\u201389.","journal-title":"Neuropsychologia."},{"key":"590_CR170","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jocn.2015.05.059","volume":"25","author":"FCF Chang","year":"2016","unstructured":"Chang FCF, Kwan V, van der Poorten D, Mahant N, Wolfe N, Ha AD, et al. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson\u2019s disease. J Clin Neurosci. 2016;25:41\u20135.","journal-title":"J Clin Neurosci."},{"issue":"5","key":"590_CR171","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.parkreldis.2014.01.019","volume":"20","author":"K Wu","year":"2014","unstructured":"Wu K, Politis M, O\u2019Sullivan SS, Lawrence AD, Warsi S, Lees A, et al. Problematic Internet use in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2014;20(5):482\u20137.","journal-title":"Parkinsonism Relat Disord."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-017-0590-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0590-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0590-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:54:47Z","timestamp":1659401687000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-017-0590-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,31]]},"references-count":171,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["590"],"URL":"https:\/\/doi.org\/10.1007\/s40264-017-0590-6","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,31]]}}}